Literature DB >> 15748550

The use of apraclonidine eyedrops to treat ptosis after the administration of botulinum toxin to the upper face.

Noah Scheinfeld1.   

Abstract

A side effect of the injection of botulinum toxin into the upper third of the face is ptosis or lid droop. A therapy recommended to treat ptosis resulting from administration of botulinum toxins A and B is Iopidine (apraclonidine 0.5 %) eye drops. Apraclonidine is an alpha2-adrenergic agonist, which causes Muller muscles to contract quickly elevating the upper eyelid 1-3 mm. Little published data discusses the use of apraclonidine to treat such ptosis. This communication discusses the extant literature on this usage. Research needs to be done to establish the utility and dosing of apraclonidine for botulinum toxin-induced ptosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15748550

Source DB:  PubMed          Journal:  Dermatol Online J        ISSN: 1087-2108


  6 in total

Review 1.  Approach to a patient with blepharoptosis.

Authors:  Samira Yadegari
Journal:  Neurol Sci       Date:  2016-06-21       Impact factor: 3.307

2.  Atropine Eye Drops Inappropriately Used for Diplopia Following Cosmetic Botulinum A Toxin Injections.

Authors:  John C Hagan
Journal:  Mo Med       Date:  2020 Jan-Feb

Review 3.  Therapeutic applications of botulinum neurotoxins in head and neck disorders.

Authors:  Ahmad Alshadwi; Mohammed Nadershah; Timothy Osborn
Journal:  Saudi Dent J       Date:  2014-12-13

4.  Understanding How to Prevent and Treat Adverse Events of Fillers and Neuromodulators.

Authors:  Glynis Ablon
Journal:  Plast Reconstr Surg Glob Open       Date:  2016-12-14

5.  The Multispecialty Toxin: A Literature Review of Botulinum Toxin.

Authors:  Karen Bach; Richard Simman
Journal:  Plast Reconstr Surg Glob Open       Date:  2022-04-06

Review 6.  Botulinum toxin-induced blepharoptosis: Anatomy, etiology, prevention, and therapeutic options.

Authors:  Mark S Nestor; Haowei Han; Anita Gade; Daniel Fischer; Yves Saban; Roberto Polselli
Journal:  J Cosmet Dermatol       Date:  2021-08-11       Impact factor: 2.189

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.